open access

Vol 53, No 3 (2022)
Review article
Submitted: 2022-04-04
Accepted: 2022-04-15
Published online: 2022-05-25
Get Citation

Artificial intelligence and chimeric antigen receptor T-cell therapy

Lidia Gil1, Maksymilian Grajek2
·
Acta Haematol Pol 2022;53(3):176-179.
Affiliations
  1. Department of Hematology and Bone Marrow Transplantation; Poznań University of Medical Sciences, 84 Szamarzewskiego str, 60-569 Poznań, Poland
  2. School of Biological Sciences, University of Manchester, Manchester, United Kingdom

open access

Vol 53, No 3 (2022)
REVIEW ARTICLE
Submitted: 2022-04-04
Accepted: 2022-04-15
Published online: 2022-05-25

Abstract

Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.

Abstract

Therapy with the use of chimeric antigen receptor T-cell (CAR T-cells) is one of the most modern medical technologies in hemato-oncology, using, thanks to the advances in molecular biology, natural anti-cancer immune mechanisms. Nowadays, it is an extremely effective complement to conventional treatment and hematopoietic cell transplantation. Ongoing clinical trials show the enormous potential of this treatment beyond hemato-oncology. We discuss in this paper the potential use of Artificial intelligence (AI) in this setting. AI has been at the cutting edge of science in recent years. It has spread from computer science to areas like medicine, economics, finance and business. The use of and research into AI in medicine have become prominent due to its versatility and capabilities.

Get Citation

Keywords

artificial intelligence, machine learning, CAR T-cell therapy

About this article
Title

Artificial intelligence and chimeric antigen receptor T-cell therapy

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 3 (2022)

Article type

Review article

Pages

176-179

Published online

2022-05-25

Page views

4612

Article views/downloads

730

DOI

10.5603/AHP.a2022.0019

Bibliographic record

Acta Haematol Pol 2022;53(3):176-179.

Keywords

artificial intelligence
machine learning
CAR T-cell therapy

Authors

Lidia Gil
Maksymilian Grajek

References (16)
  1. Erickson BJ, Korfiatis P, Akkus Z, et al. Machine learning for medical imaging. Radiographics. 2017; 37(2): 505–515.
  2. Zhou ZH. Machine learning. Springer, Singapore 2021.
  3. Jonsson A. Deep reinforcement learning in medicine. Kidney Dis (Basel). 2019; 5(1): 18–22.
  4. Zhang Z. written on behalf of AME Big-Data Clinical Trial Collaborative Group. Reinforcement learning in clinical medicine: a method to optimize dynamic treatment regime over time. Ann Transl Med. 2019; 7(14): 345.
  5. Rajpurkar P, Irvin J, Ball RL, et al. Deep learning for chest radiograph diagnosis: a retrospective comparison of the CheXNeXt algorithm to practicing radiologists. PLoS Med. 2018; 15(11): e1002686.
  6. Nicholls HL, John CR, Watson DS, et al. Reaching the end-game for GWAS: machine learning approaches for the prioritization of complex disease loci. Front Genet. 2020; 11: 350.
  7. Saria S, Henry K, Soleimani H, et al. Lead time and accuracy of trews, a machine learning-based sepsis alert. Critical Care Medicine. 2021; 50(1): 717.
  8. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–448.
  9. Schuster SJ, Bishop M, Tam C, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1): 45–56.
  10. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531–2544.
  11. Munoz JL, Wang Y, Jain P, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382(14): 1331–1342.
  12. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254): 839–852.
  13. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8): 705–716.
  14. Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematol Pol. 2020; 51(1): 6–10.
  15. Chomienne C, Sierra J, Einsele H, et al. EHA Guidance. The process of CAR-T cell therapy in Europe. HemaSphere. 2019; 3(4).
  16. Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022; 33(3): 259–275.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl